Invion Limited (IVIXF)
Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment. Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.
Sector: Drug Manufacturers - Specialty & Generic
Industry: Drug Manufacturers - Specialty & Generic
Invion Limited
- Not computed yet: no FINRA short interest has been matched to this float.
- Not published: no settled short interest on record.
- Not stated: no basis-consistent volume to divide the settled position by.
Float 59.25M · FMP free float
The cost to borrow IVIXF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
No price or settlement history available to chart.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for IVIXF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.